The impact of side-effects of antipsychotic agents on life satisfaction of schizophrenia patients: A naturalistic study

European Neuropsychopharmacology

Volumn 12, Issue 1, 2002, Pages 31-38

  Ritsner, Michael ^a,b   Ponizovsky, Alexander ^a   Endicott, Jean ^c   Nechamkin, Yakov ^a   Rauchverger, Boris ^a   Silver, Henry ^a,b   Modai, Ilan ^a,b  

^a SHA'AR MENASHE MENTAL HEALTH CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Psychosocial factors; Quality of life; Schizophrenia; Treatment adverse events

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; CLOZAPINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; HALOPERIDOL DECANOATE; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; RISPERIDONE; ZUCLOPENTHIXOL;

ADULT; ARTICLE; CONTROLLED STUDY; DISTRESS SYNDROME; DRUG INDUCED DISEASE; FEMALE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; LIFE SATISFACTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SCHIZOPHRENIA; SOCIAL PSYCHOLOGY; SYMPTOM;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; PERSONAL SATISFACTION; QUALITY OF LIFE; REGRESSION ANALYSIS; SCHIZOPHRENIA; STATISTICS, NONPARAMETRIC;

EID: 0036157049     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(01)00128-6     Document Type: Article

References (41)

1. Quality of life of schizophrenic patients on medications and implications for new drug trials
2. Quality of life and new antipsychotics in schizophrenia. Are patients better off?
3. A conceptual model of quality of life in schizophrenia: Description and preliminary clinical validation
4. Quality of life and response of negative symptoms in schizophrenia to haloperidol and the atypical antipsychotic remoxipride. The Canadian Remoxipride Group
5. Quality of life in schizophrenia: Relationship to sociodemographic factors, symptomatology and tardive dyskinesia
6. Subjective response to antipsychotics in schizophrenic patients: Clinical implications and related factors
7. Quality of Life Enjoyment and Satisfaction Questionnaire: A new measure
8. Multidimensional assessment of coping: A critical evaluation
9. Clozapine's effectiveness for patients in state hospitals: Results from a randomized trial
10. Determinants of medication compliance in schizophrenia: Empirical and clinical findings
11. Conventional versus atypical neuroleptics: Subjective quality of life in schizophrenic patients
12. Subjective experience and mental side-effects of antipsychotic treatment
13. Quality of life in schizophrenia and dysthymia
14. Selbstwirksamkeit [self-efficacy]
15. Reliability and validity of the positive and negative syndrome scale for schizophrenics
16. Quality of life in schizophrenia: Relationship to sociodemographic factors, symptomatology and tardive dyskinesia
17. Some adverse effects of antipsychotics: Prevention and treatment
18. Subjective experience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics
19. Measures of quality of life among persons with severe and persistent mental disorders
20. Insight and the clinical outcome of schizophrenic patients
21. A new depression scale designed to be sensitive to change
22. Psychopathology and quality of life in schizophrenia
23. Quality of life in first-admitted schizophrenia patients: A follow-up study
24. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: Quality of life and clinical outcomes of a randomized clinical trial
25. The Talbieh Brief Distress Inventory: A brief instrument to measure psychological distress among immigrants
26. Distress scale for adverse symptoms: A new instrument for measuring the relationship between adverse drug symptoms and associated distress
27. Differences in quality of life domains. Psychopathological and psychosocial factors in psychiatric patients
28. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia
29. Influence of novel and conventional antipsychotic medication on subjective quality of life
30. Assessment of quality of life outcomes
31. Quality of life measurement during antipsychotic drug therapy of schizophrenia
32. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life
33. The World Health Organization Quality of Life Assessment (WHOQOL): Position paper from the World Health Organization
34. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes
35. Measuring the quality of outpatient treatment for schizophrenia
36. The Multidimensional Scale of Perceived Social Support